SCHEMBL4587496

SCHEMBL4587496

Cc1cn(-c2cc(C(=O)Nc3ccc(C)c(Nc4nccn4-c4ncnc5[nH]ccc45)c3)cc(C(F)(F)F)c2)cn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 2/20 0.56
KDM4E B2RXH2 1/20 0.56
POLB P06746 1/20 0.56
RECQL P46063 1/20 0.56
MAPT P10636 1/20 0.54
MAP3K7 O43318 1/20 0.53
MAP4K2 Q12851 1/20 0.53
LYN P07948 3/20 0.50
SRC P12931 3/20 0.50
LCK P06239 2/20 0.50
HCK P08631 2/20 0.50
KDR P35968 2/20 0.50
INSR P06213 1/20 0.50
MAPK14 Q16539 1/20 0.48
MAP3K20 Q9NYL2 1/20 0.48
KIT P10721 2/20 0.47
EPHB2 P29323 1/20 0.47
ABL1 P00519 6/20 0.47
LDLR P01130 1/20 0.47
PDGFRB P09619 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4586876 0.92 MAP4K2 (0.62) CSF1RMAP3K7MAP4K2LYNSRC
SCHEMBL14097645 0.89 KDM4E (0.43) CSF1RKDM4EPOLBRECQLMAPT
SCHEMBL4586326 0.87 LYN (0.58) CSF1RMAP3K7MAP4K2LYNSRC
SCHEMBL4586222 0.86 PIKFYVE (0.57) CSF1RLYNSRCLCKHCK
SCHEMBL4587727 0.86 INSR (0.59) CSF1RMAP3K7MAP4K2LYNSRC
SCHEMBL1827777 0.84 CSF1R (0.60) CSF1RKDM4EPOLBRECQLMAPT
SCHEMBL4587871 0.84 CSF1R (0.48) CSF1RMAP3K7MAP4K2LYNSRC
SCHEMBL14097647 0.82 MAP3K7 (0.48) CSF1RMAP3K7MAP4K2LYNSRC
SCHEMBL4588492 0.82 ABL1 (0.58) CSF1RMAP4K2LYNSRCLCK
SCHEMBL4587746 0.82 CSF1R (0.56) CSF1RMAP3K7MAP4K2LYNSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080188483-A1 Compounds and Compositions as Protein Kinase Inhibitors IRM LLC (BM) 2008-08-07 US claimed
EP-1858521-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHBITORS IRM, LLC (BM) 2007-11-28 EP claimed
WO-2006101783-A2 COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2006-09-28 WO claimed
US-20080188483-A1 Compounds and Compositions as Protein Kinase Inhibitors IRM LLC (BM) 2008-08-07 US disclosed
US-20080188483-A1 Compounds and Compositions as Protein Kinase Inhibitors IRM LLC (BM) 2008-08-07 US disclosed
US-20080188483-A1 Compounds and Compositions as Protein Kinase Inhibitors IRM LLC (BM) 2008-08-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080188483-A1 Compounds and Compositions as Protein Kinase Inhibitors SRC, SGK2, PTK2B CSF1R 788/4885KDM4E 2601/4885POLB 3951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.